Page 43 - Towards personalized therapy for metastatic prostate cancer: technical validation of [18F]fluoromethylcholine

Dual-phase [18F]FCH PET/CT in prostate cancer
REFERENCES
1. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805-1814
2. Kwee SA, DeGrado TR, Talbot JN, Gutman F and Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–428
3. Fuccio C, Rubello D, Castellucci P, Marzola MC and Fanti S. Choline PET/CT for prostate cancer: main clinical 2 applications. Eur J Radiol. 2011;80:e50–56
4. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol. 2006;8:43–48
5. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60
6. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate and 18F- or 11C-choline. J Nucl Med. 2011;52:81– 89
7. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895–904
8. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–933
9. Hara T, Kosaka N and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
10. Igerc I, Kohlfürst S, Gallowitsch HJ, Matschnig S, Kresnik E, et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:976–983
11. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45–55
12. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, et al. Imaging prostate cancer with 11C-choline. J Nucl Med. 2006;47(8):1249–1254
13. Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun. 2010;31:39–45
14. DeGrado TR, Reiman RE, Price DT, Wang S and Coleman RE. Pharmacokinetics and radation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92–96
15. Kwee SA, Wei H, Sesterhenn I, Yun D and Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262–269
16. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, et al. Comparison of [18F]Fluorocholine and [18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273–280
17. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, et al. [18F]-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398
18. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part1:screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71
19. Egevad L, Mazzucchelli R and Montironi R. Implications of the International Society of Urological Pathology Modified Gleason Grading System. Arch Pathol Lab Med. 2012;136(4):426–434
20. Inoue S, Shiina H, Arichi N, Mitsui Y, Hiraoka T, et al. Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green. Can Urol Assoc J. 2011;5:254–259
21. Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol. 2010;34:1862–1867
41